Unfortunately, many people remain vaccine-hesitant. Only about half of people who were eligible got a flu shot during the 2020-2021 season, according to the U.S Centers for Disease Control and ...

those experts worry "vaccine fatigue" will keep people from getting their flu shot – and with it, a simple, safe way to protect themselves from life-threatening conditions, including heart attacks and ...

The quadrivalent recombinant influenza vaccine (RIV4) demonstrated non-inferior immune responses in children and adolescents aged 9-17 years compared with adults aged 18-49 years, with the safety ...

Moderna MRNA recently announced that the U.S. government has terminated the previously-awarded contract for the late-stage development of an mRNA-based bird flu vaccine ... which shot up +129.6 ...

US health officials are terminating a contract with Moderna Inc. worth up to $766 million to develop vaccines for bird flu, a major setback for the company as it faces additional government scrutiny ...

US President Donald Trump's administration on Wednesday canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said.

Normally, changing the strain for the vaccine wouldn’t raise questions — it's been the practice of the U.S. in recent years, following a similar model to how the flu shot is updated each year.

The White Coat Waste Project, which exposed through public records requests the five-year project on what it called "maximum pain bird flu gain-of-function experiments" on birds as young as a day old, ...

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu shot for people 50 and over, a setback for the company. The biotech ...

The delay was largely expected after Moderna said earlier this month that it does not anticipate approval of the shot until 2026 due to the need for more data on the flu vaccine. Sign up here.

After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy in eliciting antibodies in data announced earlier this month. Just two ...

Moderna has been grappling with declining revenue for both its existing COVID vaccine and its RSV shot. Experts say market turmoil has made it harder for buyers and sellers to agree on price, which ...